Home Healthcare Pharmaceuticals Thyroid Cancer Drugs Market

Thyroid Cancer Drugs Market Size, Share & Trends Analysis Report By Type (Papillary Thyroid Cancer, Follicular Thyroid Cancer, Medullary Thyroid Cancer, Anaplastic Thyroid Cancer), By Treatment (Medication, Chemotherapy, Radioactive Iodine Therapy, Hormone Therapy), By Drug Type (Sorafenib, Vandetanib, Cabozantinib, Lenvatini, Sodium Iodide I-131, Dabrafenib, Trametinib), By Route of Administration (Oral, Injectable), By End Users (Hospitals, Homecare, Specialty Clinics), By Region (North America, Europe, APAC, Middle East and Africa, LATAM), Forecasts, 2026-2034

Last Updated: August 13, 2026 | Author: Mitiksha Koul | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Thyroid Cancer Drugs Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Papillary Thyroid Cancer
    2. Follicular Thyroid Cancer
    3. Hurthle Cell Cancer
    4. Medullary Thyroid Cancer (MTC)
    5. Anaplastic Thyroid Cancer
  2. Thyroid Cancer Drugs Market, By Treatment 2022-2034 (USD MILLION/ Units)
    1. Medication
    2. Chemotherapy
    3. Radioactive Iodine (Radioiodine) Therapy
    4. Hormone Therapy
  3. Thyroid Cancer Drugs Market, By Drug Type 2022-2034 (USD MILLION/ Units)
    1. Thyroid Desiccated
    2. Sorafenib
    3. Thyrotropin Alfa
    4. Vandetanib
    5. Doxorubicin
    6. Cabozantinib
    7. Lenvatini
    8. Sodium Iodide I-131
    9. Dabrafenib
    10. Trametinib
    11. Others
  4. Thyroid Cancer Drugs Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. Oral
    2. Injectable
    3. Others
  5. Thyroid Cancer Drugs Market, By End-Users 2022-2034 (USD MILLION/ Units)
    1. Hospitals
    2. Homecare
    3. Specialty Clinics
    4. Others
  6. Regional Thyroid Cancer Drugs Market
    1. North America
      1. North America Thyroid Cancer Drugs Market By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      2. North America Thyroid Cancer Drugs Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      3. North America Thyroid Cancer Drugs Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      4. North America Thyroid Cancer Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. North America Thyroid Cancer Drugs Market By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
      6. U.S.
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      7. Canada
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
    2. Europe
      1. Europe Thyroid Cancer Drugs Market By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      2. Europe Thyroid Cancer Drugs Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      3. Europe Thyroid Cancer Drugs Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      4. Europe Thyroid Cancer Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Europe Thyroid Cancer Drugs Market By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
      6. U.K.
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      7. Germany
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      8. France
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      9. Spain
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      10. Italy
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      11. Russia
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      12. Nordic
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      13. Benelux
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      14. Rest of Europe
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
    3. APAC
      1. APAC Thyroid Cancer Drugs Market By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      2. APAC Thyroid Cancer Drugs Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      3. APAC Thyroid Cancer Drugs Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      4. APAC Thyroid Cancer Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. APAC Thyroid Cancer Drugs Market By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
      6. China
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      7. Korea
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      8. Japan
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      9. India
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      10. Australia
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      11. Singapore
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      12. Taiwan
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      13. South East Asia
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      14. Rest of Asia-Pacific
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
    4. Middle East and Africa
      1. Middle East and Africa Thyroid Cancer Drugs Market By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      2. Middle East and Africa Thyroid Cancer Drugs Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      3. Middle East and Africa Thyroid Cancer Drugs Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      4. Middle East and Africa Thyroid Cancer Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. Middle East and Africa Thyroid Cancer Drugs Market By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
      6. UAE
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      7. Turkey
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      8. Saudi Arabia
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      9. South Africa
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      10. Egypt
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      11. Nigeria
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      12. Rest of MEA
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
    5. LATAM
      1. LATAM Thyroid Cancer Drugs Market By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      2. LATAM Thyroid Cancer Drugs Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      3. LATAM Thyroid Cancer Drugs Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      4. LATAM Thyroid Cancer Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      5. LATAM Thyroid Cancer Drugs Market By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
      6. Brazil
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      7. Mexico
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      8. Argentina
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      9. Chile
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      10. Colombia
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
      11. Rest of LATAM
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
        6. Medication
        7. Chemotherapy
        8. Radioactive Iodine (Radioiodine) Therapy
        9. Hormone Therapy
        10. Thyroid Desiccated
        11. Sorafenib
        12. Thyrotropin Alfa
        13. Vandetanib
        14. Doxorubicin
        15. Cabozantinib
        16. Lenvatini
        17. Sodium Iodide I-131
        18. Dabrafenib
        19. Trametinib
        20. Others
        21. Oral
        22. Injectable
        23. Others
        24. Hospitals
        25. Homecare
        26. Specialty Clinics
        27. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.